|
Age (s.d)
|
42.7 (12.7)
|
44.8 (12.1)
|
|
Disease duration (s.d)
|
20.3 (13.4)
|
20.3 (13.2)
|
|
Male (%)
|
45 (65.2)
|
49 (75.4)
|
|
Iritis2 (%)
|
13/58 (22.4)
|
14/52 (26.9)
|
|
Inflammatory bowel disease2 (%)
|
6/58 (10.4)
|
2/52 (3.9)
|
|
Medication
| | |
|
■ non-steroidal anti-inflammatory drug (%)
|
44/66 (66.7)
|
53/62 (85.5)
|
|
■ steroid (%)
|
2/67 (3.0)
|
0/63 (0.0)
|
|
■ disease modifying antirheumatic drug (%)
|
8/67 (11.9)
|
5/63 (7.9)
|
|
Global Well-being (scale 0–10)
|
3.2 (2.0)
|
4.1 (2.5)
|
|
Disease activity (scale 0–10)
|
3.5 (1.9)
|
4.1 (2.2)
|
|
Function (scale 0–10)
|
3.1 (2.5)
|
4.2 (3.0)
|
